Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Net Margin: 2017-2025

Historic Net Margin for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to -834.87%.

  • Protagonist Therapeutics' Net Margin fell 12449.00% to -834.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.54%, marking a year-over-year decrease of 3192.00%. This contributed to the annual value of 63.34% for FY2024, which is 19494.00% up from last year.
  • Protagonist Therapeutics' Net Margin amounted to -834.87% in Q3 2025, which was down 33.05% from -627.46% recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Net Margin ranged from a high of 180,342.11% in Q4 2022 and a low of -4,551.00% during Q2 2022.
  • In the last 3 years, Protagonist Therapeutics' Net Margin had a median value of -334.31% in 2025 and averaged -341.53%.
  • In the last 5 years, Protagonist Therapeutics' Net Margin soared by 18,077,326bps in 2022 and then crashed by 18,028,744bps in 2023.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Net Margin stood at -431.16% in 2021, then spiked by 18,077,326bps to 180,342.11% in 2022, then tumbled by 18,028,744bps to 54.67% in 2023, then surged by 2,513bps to 79.80% in 2024, then slumped by 12,449bps to -834.87% in 2025.
  • Its Net Margin was -834.87% in Q3 2025, compared to -627.46% in Q2 2025 and -41.15% in Q1 2025.